NEDD4L and esophageal squamous cell carcinoma: Additionally, investigating potential therapeutic interventions that target NEDD4L or its downstream effectors could pave the way for novel treatments in cancer therapy, not limited to ESCC but potentially applicable to other cancers with dysregulated ferroptosis pathways.